Are these 3 shares simply the best Brexit buys after today’s results?

Could these stocks be a cure for Brexit blues?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Results season is in full swing but UK-focused companies have been unable to give much guidance on the business consequences of the Brexit vote. “Too soon to tell” has been the refrain. Could three FTSE 100 multinational giants with results out today be a cure for Brexit blues?

Diageo

As in recent years, exchange rates adversely impacted reported numbers from drinks giant Diageo (LSE: DGE). Reported net sales of £10.5bn for the year to 30 June were down 3% but up 3% on an organic basis. Similarly, operating profit before exceptional items declined 2% but increased 3% organically.

Earnings per share (EPS) before exceptional items moved 1% higher (versus a City consensus for a 1% fall), and the board lifted the dividend by 5%, which was also ahead of consensus. Chief executive Ivan Menezes said the results “position us well to deliver a stronger performance” in fiscal 2017.

It’s important to the group “that the UK continues to benefit from open access to the EU as well as favourable international trade agreements,” but the immediate tangible impact of the Brexit vote will be a significant benefit from weakened sterling. At current exchange rates, Diageo estimates a favourable impact on net sales of £1.1bn, with operating profit boosted by £370m.

The shares are modestly higher at 2,145p, as I’m writing, putting the company on a forward price-to-earnings (P/E) ratio of 21 with a prospective dividend yield of 2.9%. Momentum is clearly returning to this high-quality business after a few sluggish years, and the stock looks very buyable to me at current levels.

British American Tobacco

British American Tobacco (LSE: BATS) announced strong half-year numbers this morning. Reported revenue increased 4.2%, but 7.8% at constant exchange rates. Underlying EPS grew 10.9% (13.4% at constant currency), and the board lifted the interim dividend by 4%.

Looking ahead to the full year, management said it believes the Brexit vote will have no material impact on the group’s underlying business.

The shares are modestly higher in morning trading. At 4,800p, the forward P/E is 20, with a prospective dividend yield of 3.4%. As another high-class, globally-diversified and defensive business, I rate British American Tobacco as a great buy-and-hold pick.

Smith & Nephew

Medical devices group Smith & Nephew (LSE: SN) reports in dollars, and foreign exchange rates didn’t have a major impact on revenue in its half-year numbers announced today. Reported top-line growth was 2%, while underlying growth was 3%.

However, an expected transactional currency headwind hit numbers lower down the income statement, feeding through to an 18% decline in reported EPS (underlying EPS was 5% lower). More positively, the current dollar/sterling exchange rate will have a significant positive impact on the interim dividend, with a 4% dollar increase translating into a sterling rise of over 20%.

Smith & Nephew believes Brexit “will not have a significant impact on our ability to conduct business into and out of the EU in the short-to-medium term,” while chief executive Olivier Bohuon expressed his confidence in “our positioning and long-term prospects.”

The shares are lower in morning trading at 1,240p. On a forward P/E of 20 with a well-covered 2% dividend yield, this is another stock I reckon is worth buying to beat the Brexit blues.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Diageo. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »